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(of 18) imported MV strains between 2003-2007. Additional
information is needed to track strains prior to 2000.
Conclusions: Seven genotypes (A, D3, D5, D9, G2, H1
and H2) were recognized from MV cases during 1992-2007.
Viruses of genotype H1 and D3 are implicated as indigenous
strains in Taiwan. In Taiwan, one-dose measles immunization
program began in 1978, and two-dose policy started in 1984.
Two catch-up campaigns were implemented in 1992—1994
and 2002—2004 separately. The vaccine coverage rate with
1st dose MV (for 12—15 months) and 2nd dose MMR (for
6 years old) was over 90% and 95% since 1996. The mul-
tiple genotypes and sporadic cases discovered after 2003
(except 2 cases in 2005) were all imported. The measles
mass vaccination program has successfully interrupted the
transmission of indigenous MV in Taiwan.
doi:10.1016/j.ijid.2008.05.369
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Background and Aim: The GlaxoSmithKline oral human
attenuated rotavirus (RV) vaccine RIX4414 (RotarixTM) has
been shown to be highly effective for the prevention of
RV gastroenteritis (GE) globally. Infants participating in a
double-blind, randomized, placebo-controlled and multi-
centre trial conducted in Singapore, Hong Kong and Taiwan
(e-track107070,107072,107076/NCT444563/028/029/030)
were followed up to approximately two years of age to
assess protection against severe RVGE.
Methods: 10708 healthy infants, 6—17 weeks of age at
Dose 1 were enrolled and randomised into two groups (1:1)
to receive 2 doses of RIX4414 vaccine or placebo at a 0,1-2
month schedule. Routine vaccinations were given concomi-
tantly. Vaccine efﬁcacy (VE) was calculated from 2-weeks
post-Dose2 until approximately 24months of age. Severity of
RVGE was assessed using the 20-point Vesikari scale (severe
RVGE ≥11). Diarrhoeal stool samples were analyzed for RV
by ELISA and typed by RT-PCR based method. Safety data
was collected throughout the study.
Results: During the efﬁcacy follow-up period (mean dura-
tion of 20 months), 2 severe RVGE episodes were reported in
RIX4414 and 51 in the placebo group. VE against severe RVGE
was 96.1% (95%CI:85.1;99.5), 100.0% (95%CI:80.8;100.0)
against wild-type G1 and 93.6% (95%CI:74.7;99.3) against
pooled non-G1 RV types(G2,G3,G9) proving broad pro-
tection by RIX4414. Efﬁcacy against hospitalized RVGE
was 93.8% (95%CI:80.6;98.8). An overall reduction of
29.2%(95%CI:12.9;42.5) of hospitalization due to all cause
GE episode was observed compared to placebo. There was
no clinically meaningful difference between RIX4414 group
and the placebo group for SAEs reported during the study.
Conclusions: Presented results demonstrate that in an
Asian urban setting, two oral doses of RIX4414 (RotarixTM)
offer high and sustained protection against severe RVGE dur-
ing the ﬁrst two years of life when the disease burden is
highest. These data are in line with efﬁcacy results obtained
for RotarixTM in Europe.
doi:10.1016/j.ijid.2008.05.370
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Background: 6—12 week-old healthy infants were ran-
domized to receive 3 oral doses of the pentavalent rotavirus
vaccine (PRV), RotaTeqTM, or placebo in the Rotavirus Efﬁ-
cacy and Safety Trial (REST). To determine if PRV remains
efﬁcacious beyond 2 years after vaccination, approximately
21,000 REST infants in the safety cohort in Finland were fol-
lowed for healthcare resource utilization (HCRU), deﬁned
as rotavirus gastroenteritis (RGE)-associated hospitaliza-
tions and/or emergency department (ED) visits, in a Finnish
Extension Study (FES) for up to 3.1 years after completing
vaccination.
Methods: FES infants were contacted every 12 weeks to
determine whether they had any RGE-related HCRU. RGE
was deﬁned as forceful vomiting and/or ≥3 watery or looser-
than-normal stool within a 24-hour period and detection of
rotavirus antigen by enzyme immunoassay, plaque assay, and
PCR assays to determine the P and G types. Infants with RGE,
who received 3 vaccine doses, were included in the analysis,
and follow-up started 14 days after dose 3.
Results: The maximum follow-up time in REST was 2 years
(730.5 days) and in REST and FES was 3.1 years (1126 days).
Overall, PRV reduced the rate of RGE-associated HCRU,
regardless of rotavirus serotype, by 94% (95% conﬁdence
interval [CI]: 91.3, 95.9) for up to 3.1 years after the third
dose, demonstrating an overall reduction of HCRU similar to
that of REST (95% [95% CI: 91.5, 96.5]).
Conclusion: RGE-associated HCRU continues to be com-
mon in the second year of life but decreases in the third year
of life. PRV signiﬁcantly reduced RGE-associated hospitaliza-
tions and ED visits among FES infants, regardless of serotype,
for up to 3.1 years of follow-up after completing vaccina-
tion. The results of FES are consistent with the results of
REST and conﬁrm that the efﬁcacy of PRV remains consis-
tent beyond two years, and up to 3.1 years, after completing
vaccination.
doi:10.1016/j.ijid.2008.05.371
